Skip to main content

Table 6 Concomitant LABA and ICS users stratified by age group, sex, and inhaler type (“Combined Inhalers”, “Separate Inhalers”, “Combinations”) for the year 2008*

From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

  Combined Inhalers [fixed LABA/ICS) Separate Inhalers [non-fixed LABA/ICS] Combinations All concomitant LABA/ICS categories
Age group Male Female Male Female Male Female Male Female
0-9 3,262 (76.9%) 1,735 (75.8%) 219 (5.2%) 135 (5.9%) 761 (17.9%) 418 (18.3%) 4,242 (100%) 2,288 (100%)
10-19 9,121 (88.2%) 6,208 (87.9%) 550 (5.3%) 422 (6.0%) 676 (6.5%) 430 (6.1%) 10,347 (100%) 7,060 (100%)
20-29 6,052 (90.9%) 7,208 (89.9%) 436 (6.5%) 525 (6.6%) 172 (2.6%) 281 (3.5%) 6,660 (100%) 8,014 (100%)
30-39 7,053 (88.5%) 9,034 (87.2%) 669 (8.4%) 885 (8.5%) 250 (3.1%) 444 (4.3%) 7,972 (100%) 10,363 (100%)
40-49 10,015 (87.1%) 14,110 (86.0%) 1,102 (9.6%) 1,515 (9.2%) 386 (3.4%) 788 (4.8%) 11,503 (100%) 16,413 (100%)
50-59 8,777 (85.1%) 13,239 (84.8%) 1,120 (10.9%) 1,624 (10.4%) 413 (4.0%) 748 (4.8%) 10,310 (100%) 15,611 (100%)
60-69 10,454 (83.7%) 14,200 (84.1%) 1,545 (12.4%) 1,906 (11.3%) 489 (3.9%) 779 (4.6%) 12,488 (100%) 16,885 (100%)
70-79 9,428 (83.5%) 12,121 (84.5%) 1,368 (12.1%) 1,594 (11.1%) 495 (4.4%) 625 (4.4%) 11,291 (100%) 14,340 (100%)
80-89 3,469 (85.2%) 5,712 (86.1%) 433 (10.6%) 650 (9.8%) 169 (4.2%) 270 (4.1%) 4,071 (100%) 6,632 (100%)
90+ 178 (87.3%) 408 (87.7%) 17 (8.3%) 35 (7.5%) 9 (4.4%) 22 (4.7%) 204 (100%) 465 (100%)
Total 67,809 (85.7%) 83,975 (85.6%) 7,459 (9.4%) 9,291 (9.5%) 3,820 (4.8%) 4,805 (4.9%) 79,088 (100%) 98,071 (100%)
  1. *Concomitant LABA/ICS treatment categories percentage values were calculated for each age group and sex separately.